270 related articles for article (PubMed ID: 28893587)
1. Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database.
Monticello TM; Jones TW; Dambach DM; Potter DM; Bolt MW; Liu M; Keller DA; Hart TK; Kadambi VJ
Toxicol Appl Pharmacol; 2017 Nov; 334():100-109. PubMed ID: 28893587
[TBL] [Abstract][Full Text] [Related]
2. Drug development and nonclinical to clinical translational databases: past and current efforts.
Monticello TM
Toxicol Pathol; 2015 Jan; 43(1):57-61. PubMed ID: 25389276
[TBL] [Abstract][Full Text] [Related]
3. Prediction of clinical risks by analysis of preclinical and clinical adverse events.
Clark M
J Biomed Inform; 2015 Apr; 54():167-73. PubMed ID: 25746390
[TBL] [Abstract][Full Text] [Related]
4. The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.
Ewart L; Aylott M; Deurinck M; Engwall M; Gallacher DJ; Geys H; Jarvis P; Ju H; Leishman D; Leong L; McMahon N; Mead A; Milliken P; Suter W; Teisman A; Van Ammel K; Vargas HM; Wallis R; Valentin JP
Toxicol Sci; 2014 Dec; 142(2):427-35. PubMed ID: 25246669
[TBL] [Abstract][Full Text] [Related]
5. Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations.
Bailey J; Balls M
BMC Med Ethics; 2019 Mar; 20(1):16. PubMed ID: 30823899
[TBL] [Abstract][Full Text] [Related]
6. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective.
Butler LD; Guzzie-Peck P; Hartke J; Bogdanffy MS; Will Y; Diaz D; Mortimer-Cassen E; Derzi M; Greene N; DeGeorge JJ
Regul Toxicol Pharmacol; 2017 Jul; 87 Suppl 3():S1-S15. PubMed ID: 28483710
[TBL] [Abstract][Full Text] [Related]
7. Translation of nonclinical to clinical safety findings for 27 biotherapeutics.
Leach MW; Rana P; Hu W; Mittapalli RK; Pinkstaff J; Potter D; Qiu XM; Ramaiah L; Rohde C; Xia F; Khan KN
Toxicol Appl Pharmacol; 2024 Mar; 484():116854. PubMed ID: 38346540
[TBL] [Abstract][Full Text] [Related]
8. The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals.
van Meer PJ; Graham ML; Schuurman HJ
Eur J Pharmacol; 2015 Jul; 759():3-13. PubMed ID: 25818943
[TBL] [Abstract][Full Text] [Related]
9. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
10. Insights into toxicology, safety pharmacology, and drug dependence testing: The performance and predictive values of nonclinical tests.
Suarez-Torres JD; Ciangherotti CE; Jimenez-Orozco FA
J Pharmacol Toxicol Methods; 2020; 103():106684. PubMed ID: 32173560
[TBL] [Abstract][Full Text] [Related]
11. A translational pharmacology approach to understanding the predictive value of abuse potential assessments.
Horton DB; Potter DM; Mead AN
Behav Pharmacol; 2013 Sep; 24(5-6):410-36. PubMed ID: 23873088
[TBL] [Abstract][Full Text] [Related]
12. Regulatory Forum Opinion Piece
Morgan SJ; Couch J; Guzzie-Peck P; Keller DA; Kemper R; Otieno MA; Schulingkamp RJ; Jones TW
Toxicol Pathol; 2017 Apr; 45(3):372-380. PubMed ID: 28351296
[TBL] [Abstract][Full Text] [Related]
13. Drug safety testing paradigm, current progress and future challenges: an overview.
Ahuja V; Sharma S
J Appl Toxicol; 2014 Jun; 34(6):576-94. PubMed ID: 24777877
[TBL] [Abstract][Full Text] [Related]
14. Metabolites in safety testing.
Robison TW; Jacobs A
Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
[TBL] [Abstract][Full Text] [Related]
15. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products.
Cavagnaro J; Silva Lima B
Eur J Pharmacol; 2015 Jul; 759():51-62. PubMed ID: 25814257
[TBL] [Abstract][Full Text] [Related]
16. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.
Ivens IA; Achanzar W; Baumann A; Brändli-Baiocco A; Cavagnaro J; Dempster M; Depelchin BO; Rovira AR; Dill-Morton L; Lane JH; Reipert BM; Salcedo T; Schweighardt B; Tsuruda LS; Turecek PL; Sims J
Toxicol Pathol; 2015 Oct; 43(7):959-83. PubMed ID: 26239651
[TBL] [Abstract][Full Text] [Related]
17. Integrated and translational nonclinical in vivo cardiovascular risk assessment: gaps and opportunities.
Berridge BR; Hoffmann P; Turk JR; Sellke F; Gintant G; Hirkaler G; Dreher K; Schultze AE; Walker D; Edmunds N; Halpern W; Falls J; Sanders M; Pettit SD
Regul Toxicol Pharmacol; 2013 Feb; 65(1):38-46. PubMed ID: 23044254
[TBL] [Abstract][Full Text] [Related]
18. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
[TBL] [Abstract][Full Text] [Related]
19. The Use of Minipigs for Preclinical Safety Assessment by the Pharmaceutical Industry: Results of an IQ DruSafe Minipig Survey.
Colleton C; Brewster D; Chester A; Clarke DO; Heining P; Olaharski A; Graziano M
Toxicol Pathol; 2016 Apr; 44(3):458-66. PubMed ID: 27006130
[TBL] [Abstract][Full Text] [Related]
20. Use of animal models of human disease for nonclinical safety assessment of novel pharmaceuticals.
Morgan SJ; Elangbam CS; Berens S; Janovitz E; Vitsky A; Zabka T; Conour L
Toxicol Pathol; 2013; 41(3):508-18. PubMed ID: 22968286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
